UPDATE: Canaccord Genuity Downgrades MAP Pharmaceuticals to Hold Following Takeover
Canaccord Genuity downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold and raised the price target from $23.00 to $25.00.
Canaccord Genuity commented, "Post yesterday's announcement of Allergan's (AGN) intention to acquire Map Pharmaceuticals (MAPP) and subsequent conference call we're downgrading MAPP from Buy to HOLD and raising our price target to $25, in line with the deal price. The stock was +59% today, closing modestly below the announced acquisition price, and we expect a successful closing in March. We like the fit with AGN, and post call and follow-up we haven't heard anything that changes our view."
MAP Pharmaceuticals closed at $24.71 on Wednesday.
Latest Ratings for MAPP
|Feb 2013||Ladenburg Thalmann||Downgrades||Buy||Neutral|
|Jan 2013||Deutsche Bank||Downgrades||Buy||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.